In vitro, SHP knockdown enhances innate immune components and hepatocellular steatosis, and recapitulates a cholestatic gene signature that has been observed in patients with MASH, suggesting that increased SHP nuclear translocation may serve to mitigate steatosis and innate immune responses, as well as prevent the cholestatic phenotype. The gene discussed is NR0B2; the disease is steatosis.